Processing

Please wait...

Settings

Settings

Goto Application

1. WO2009015248 - TREATMENT OF POST-TRAUMATIC STRESS DISORDER

Publication Number WO/2009/015248
Publication Date 29.01.2009
International Application No. PCT/US2008/070948
International Filing Date 23.07.2008
IPC
A61K 31/535 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
CPC
A61K 31/4164
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
A61K 31/535
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applicants
  • SYNOSIA THERAPEUTICS [US]/[US] (AllExceptUS)
  • WOIWODE, Tom [CH]/[US] (UsOnly)
  • MORAN, Mark [CH]/[US] (UsOnly)
Inventors
  • WOIWODE, Tom
  • MORAN, Mark
Agents
  • BANAIT, Narinder, S.
Priority Data
60/935,03623.07.2007US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TREATMENT OF POST-TRAUMATIC STRESS DISORDER
(FR) TRAITEMENT D'UN TROUBLE DE STRESS POST-TRAUMATIQUE
Abstract
(EN)
Provided are methods of treating a patient diagnosed with post-traumatic stress disorder, by administering to the patient a therapeutically effective amount of Compound A. Also provided are methods of improving resilience in a patient by administering a therapeutically effective amount of Compound A. Also provided are methods of diagnosing post-traumatic stress disorder in a patient by administering to the patient a therapeutically effective amount of Compound A and assessing at least one of sign, symptom, or symptom cluster of post-traumatic stress disorder; and diagnosing post-traumatic stress disorder in the patient if the Compound A reduces at least one of sign, symptom, and symptom cluster of post-traumatic stress disorder.
(FR)
L'invention concerne des procédés de traitement d'un patient chez qui on a diagnostiqué un trouble de stress post-traumatique par administration d'une quantité thérapeutiquement efficace de composé A. L'invention propose également des procédés d'amélioration de la résilience d'un patient par administration d'une quantité thérapeutiquement efficace de composé A. L'invention propose enfin des procédés de diagnostic d'un trouble de stress post-traumatique chez un patient en administrant une quantité thérapeutiquement efficace de composé A et en évaluant au moins un signe, un symptôme ou un agrégat de symptômes d'un trouble de stress post-traumatique, ce qui permet de diagnostiquer un trouble de stress post-traumatique si le composé A réduit au moins un signe, un symptôme et un agrégat de symptôme de trouble de stress post-traumatique chez le patient.
Latest bibliographic data on file with the International Bureau